anastrozole

P2, N=17, Completed, Mayo Clinic | Active, not recruiting --> Completed | Trial completion date: Jun 2026 --> Mar 2026

P1, N=30, Recruiting, Northwestern University | Not yet recruiting --> Recruiting

P1, N=30, Not yet recruiting, Northwestern University | N=75 --> 30

Despite aggressive critical care management, she experienced cardiac arrest and died. This case may represent the first reported fatal occurrence of anastrozole-associated TLS in advanced breast cancer, underscoring the need for vigilance for TLS even with hormonal agents traditionally considered low-toxicity.

P3, N=1556, Suspended, Alliance for Clinical Trials in Oncology | N=1156 --> 1556

P2/3, N=1014, Active, not recruiting, IRCCS Ospedale Policlinico San Martino | Not yet recruiting --> Active, not recruiting

P3, N=1978, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting | Initiation date: Jul 2026 --> Feb 2027

Patients were randomized (1:1) to receive fovinaciclib, 200 mg (orally once daily on days 1 to 21), or placebo plus letrozole, 2.5 mg, or anastrozole, 1 mg (orally once daily on days 1 to 28), in 28-day cycles. Premenopausal or perimenopausal patients also received goserelin, 3.6 mg (subcutaneously on day 1)...In this randomized clinical trial, adding fovinaciclib to first-line aromatase inhibitor conferred significant and clinically meaningful PFS benefit and consistent improvements in other efficacy outcomes, along with manageable safety and unaffected quality of life. ClinicalTrials.gov Identifier: NCT05439499.

Positron emission tomography/computed tomography in January 2023 raised concern for recurrence, and exploratory laparoscopy in March 2023 documented peritoneal metastatic disease, followed by four cycles of cisplatin given within the then-prevailing carcinoma-based diagnostic framework...After external review, everolimus plus anastrozole was started in May 2025...At the most recent available follow-up in April 2026, the patient had no documented death and remained under postoperative surveillance. Discussion and This case illustrates the diagnostic importance of repeated tissue reassessment and the practical value of minimally invasive surgery as a relatively low-burden means of resection, restaging, and tissue acquisition in a rare molecularly reclassified adnexal tumor.

We preliminarily developed an intervention that appears engaging, relevant, and acceptable for patients to self-monitor their symptoms. Further revisions informed by user feedback will be incorporated after testing ENABLE (Medication Brand Changes in Hormone Therapy for Breast Cancer: A Community Pharmacy Intervention Development to Improve Patients' Adherence and Quality of Life) in community pharmacies.

P3, N=1050, Active, not recruiting, Borstkanker Onderzoek Groep | Trial completion date: Dec 2025 --> Dec 2028

P1/2, N=100, Not yet recruiting, University of Illinois at Chicago